Indian Experience with Vericiguat: A Review Based upon Case Series
Upendra Kaul1, Jamshed Dalal2, Jagdish Hiremath3
1Batra Hospital and Medical Research Centre, Delhi, India, Corresponding Author.
The Journal of the Association of Physicians of India
|October 11, 2024
Summary
Vericiguat, a novel therapy for heart failure (HF), shows promise in reducing hospitalizations for worsening heart failure (WHF). Early initiation may benefit specific patient groups at high risk.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Heart failure (HF) frequently leads to hospitalizations and disease progression.
- Current treatments for HF aim to reduce cardiovascular events but residual risk remains.
- Worsening heart failure (WHF) signifies a critical stage requiring optimized therapeutic strategies.
Purpose of the Study:
- To explore the potential benefits of early vericiguat initiation in patients experiencing WHF.
- To identify specific patient profiles who may gain the most from early vericiguat therapy.
- To assess vericiguat as a promising therapeutic option for managing WHF.
Main Methods:
- This article reviews the potential benefits of early vericiguat initiation.
- The study focuses on four distinct patient profiles presenting with WHF.
- Analysis is based on existing data and clinical understanding of vericiguat's mechanism.
Main Results:
- Vericiguat, a soluble guanylate cyclase (sGC) stimulator, is a new therapeutic agent.
- Early initiation of vericiguat may offer advantages in specific patient cohorts.
- The drug presents a promising option for patients with signs of worsening heart failure.
Conclusions:
- Vericiguat represents a potential advancement in managing heart failure with worsening signs.
- Early intervention with vericiguat could be a valuable strategy for select HF patients.
- Further investigation into early vericiguat use in WHF is warranted.
Related Concept Videos
01:19Pharmacovigilance
783
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
783
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K